Literature DB >> 25339453

MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.

Xiaojun Ge1, Limei Zheng2, Min Huang3, Yonglun Wang2, Feng Bi1.   

Abstract

The aim of the present study was to establish, characterize and elucidate the potential mechanisms of acquired gefitinb resistance, using the A549 human lung cancer cell line. A gefitinib-resistant A549 sub-clone was established by exposure to escalating gefitinib concentrations over a period of 16-24 months. Half maximal inhibitory concentration (IC50) values were quantified using a real time cytotoxicity assay. The expression profiles of the parent and resistant sub-clone A549 cells were detected using the µParaflo® Microfluidics Biochip microRNA (miRNA) Microarray. The ArrayPro software was used to analyze the differential expression levels of the miRNA, and bioinformatics software was used to predict the potential target genes of the differentially expressed miRNAs. Quantitative polymerase chain reaction (qPCR) was used to confirm the results of the miRNA microarray. A miRNA mimic was transfected into the gefitinib-resistant cells, in order to predict target gene interaction effects, following gefitinib treatment. Protein expression level differences were confirmed by western-blot analysis. Real time cytotoxicity assays revealed a 3-fold increase in the IC50 values of the gefitinib-resistant sub-clones, as compared with the parent cells. There were marked morphological differences between the parent and resistant cells. In the microarray analysis, the gefitinib-resistant sub-clones had 25 upregulated and 18 downregulated miRNAs, as compared with the parent cells. The qPCR revealed that miR-7 was significantly downregulated, which was concordant with the results of the microarray. The results of the present study suggest that miR-7 may significantly improve the sensitivity of cancer cells to gefitinib. The data presented in the present study provides an experimental basis and theory that miRNAs may be involved in acquired gefitinib-resistance of lung adenocarcinoma, and miR-7 may have potential clinical effects in the reversal of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339453     DOI: 10.3892/mmr.2014.2757

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  MicroRNAs are Necessary for BMP-7-induced Dendritic Growth in Cultured Rat Sympathetic Neurons.

Authors:  Kristina Pravoverov; Katherine Whiting; Slesha Thapa; Trevor Bushong; Karen Trang; Pamela J Lein; Vidya Chandrasekaran
Journal:  Cell Mol Neurobiol       Date:  2019-05-18       Impact factor: 5.046

Review 2.  Mechanisms of tumor cell resistance to the current targeted-therapy agents.

Authors:  Gholamreza Khamisipour; Farhad Jadidi-Niaragh; Abdolreza Sotoodeh Jahromi; Keivan Zandi; Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2016-05-07

3.  MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma.

Authors:  Qiqi Mao; Tao Quan; Bin Luo; Xuefeng Guo; Lei Liu; Qinghui Zheng
Journal:  Tumour Biol       Date:  2015-07-30

Review 4.  Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.

Authors:  Thomas K Sin; Fengfeng Wang; Fei Meng; S C Cesar Wong; William C S Cho; Parco M Siu; Lawrence W C Chan; Benjamin Y M Yung
Journal:  Int J Mol Sci       Date:  2016-02-15       Impact factor: 5.923

5.  BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma.

Authors:  Yushun Gao; Bing Wang; Shugeng Gao
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

6.  BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells.

Authors:  Taeho Kwon; Nisansala Chandimali; Do Luong Huynh; Jiao Jiao Zhang; Nameun Kim; Yesol Bak; Do-Young Yoon; Dae-Yeul Yu; Jae Cheol Lee; Meeta Gera; Mrinmoy Ghosh; Yang Ho Park; Dong Kee Jeong
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

7.  The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis.

Authors:  ZheXing Wang; LiMing Pan; HaiXiang Yu; Yue Wang
Journal:  Biosci Rep       Date:  2018-08-29       Impact factor: 3.840

8.  MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.

Authors:  Qing Li; Yueming Wang; Jingdong He
Journal:  J Clin Lab Anal       Date:  2021-05-31       Impact factor: 2.352

Review 9.  Clinical Potential of microRNA-7 in Cancer.

Authors:  Jessica L Horsham; Felicity C Kalinowski; Michael R Epis; Clarissa Ganda; Rikki A M Brown; Peter J Leedman
Journal:  J Clin Med       Date:  2015-08-25       Impact factor: 4.241

10.  miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.

Authors:  Xiaoyan Sun; Jun Li; Yanhong Sun; Yi Zhang; Liyun Dong; Chen Shen; Liu Yang; Ming Yang; Yan Li; Guanxin Shen; Yating Tu; Juan Tao
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.